QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:IMABI-Mab Stock Price, Forecast & News

$29.50
-0.58 (-1.93 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$28.91
Now: $29.50
$30.30
50-Day Range
$28.24
MA: $30.24
$33.31
52-Week Range
$9.30
Now: $29.50
$35.00
Volume144,654 shs
Average Volume85,050 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for immuno-oncology; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMAB
CUSIPN/A
CIKN/A
Phone86-21-6057-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.31 million

Profitability

Miscellaneous

Employees185
Market Cap$1.68 billion
Next Earnings Date8/31/2020 (Estimated)
OptionableNot Optionable
$29.50
-0.58 (-1.93 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











I-Mab (NASDAQ:IMAB) Frequently Asked Questions

How has I-Mab's stock been impacted by COVID-19 (Coronavirus)?

I-Mab's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMAB stock has increased by 116.6% and is now trading at $29.50.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of I-Mab?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for I-Mab
.

When is I-Mab's next earnings date?

I-Mab is scheduled to release its next quarterly earnings announcement on Monday, August 31st 2020.
View our earnings forecast for I-Mab
.

What price target have analysts set for IMAB?

4 analysts have issued 1 year price objectives for I-Mab's shares. Their forecasts range from $16.00 to $50.00. On average, they anticipate I-Mab's share price to reach $25.51 in the next twelve months. This suggests that the stock has a possible downside of 13.5%.
View analysts' price targets for I-Mab
.

Has I-Mab been receiving favorable news coverage?

News stories about IMAB stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. I-Mab earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about I-Mab
.

Who are some of I-Mab's key competitors?

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include ServiceNow (NOW), NVIDIA (NVDA), Intel (INTC), Broadcom (AVGO), Alibaba Group (BABA), Cisco Systems (CSCO), Dropbox (DBX), Walt Disney (DIS), Gilead Sciences (GILD) and Eli Lilly And Co (LLY).

Who are I-Mab's key executives?

I-Mab's management team includes the following people:
  • Dr. Joan Huaqiong Shen M.D., Ph.D., CEO & Director (Age 57)
  • Dr. Zheru Zhang Ph.D., Pres & Director (Age 56)
  • Dr. Jingwu Zhang Zang M.D., Ph.D., Founder, Honorary Chairman & Director (Age 63)
  • Mr. Jielun Zhu, CFO & Director (Age 43)
  • Dr. Lili Qian Ph.D., VP of Operations (Age 37)

When did I-Mab IPO?

(IMAB) raised $100 million in an IPO on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

What is I-Mab's stock symbol?

I-Mab trades on the NASDAQ under the ticker symbol "IMAB."

When did I-Mab's lock-up period expire?

I-Mab's lock-up period expired on Wednesday, July 15th. I-Mab had issued 7,407,400 shares in its public offering on January 17th. The total size of the offering was $103,703,600 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are I-Mab's major shareholders?

I-Mab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vident Investment Advisory LLC (0.03%) and Vident Investment Advisory LLC (0.03%).

Which institutional investors are selling I-Mab stock?

IMAB stock was sold by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, and Vident Investment Advisory LLC.

How do I buy shares of I-Mab?

Shares of IMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is I-Mab's stock price today?

One share of IMAB stock can currently be purchased for approximately $29.50.

How big of a company is I-Mab?

I-Mab has a market capitalization of $1.68 billion and generates $4.31 million in revenue each year. I-Mab employs 185 workers across the globe.

What is I-Mab's official website?

The official website for I-Mab is www.i-mabbiopharma.com.

How can I contact I-Mab?

I-Mab's mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6057-8000 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.